History of drugs for thrombotic disease. Discovery, development, and directions for the future

Circulation

Volumn 89, Issue 1, 1994, Pages 432-449

  Mueller, Richard L ^a   Scheidt, Stephen ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Aspirin; Thrombolytics

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; WARFARIN;

ANIMAL; ARTICLE; CANADA; EUROPE; HISTORY; HISTORY OF MEDICINE; HUMAN; THROMBOSIS; UNITED STATES;

ANIMAL; ASPIRIN; CANADA; EUROPE; FIBRINOLYTIC AGENTS; HEPARIN; HISTORY OF MEDICINE, 17TH CENT.; HISTORY OF MEDICINE, 18TH CENT.; HISTORY OF MEDICINE, 19TH CENT.; HISTORY OF MEDICINE, 20TH CENT.; HISTORY OF MEDICINE, ANCIENT; HUMAN; PORTRAITS; THROMBOSIS; UNITED STATES; WARFARIN;

EID: 0028062665     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.cir.89.1.432     Document Type: Article

References (145)

1. Synthetic Organic Chemicals: US Production and Sales 1985. Publication No. 1892. Washington, DC: US Government Printing Office; 1986.
2. Mann CC, Plummer ML. The Aspirin Wars: Money, Medicine and 100 Years of Rampant Competition. New York, NY: Alfred A Knopf Inc; 1991:1-420.
3. Schindler PE. Aspirin Therapy. New York, NY: Walker and Company; 1978:1-134.
4. Gross M, Greenberg LA. The Salicylates: A Critical Bibliographic Review. New Haven, Conn: Hillhouse Press; 1948:1-8.
5. Roueche B. The Incurable Wound and Further Narratives of Medical Detection. Boston, Mass: Little, Brown & Co; 1957: 89-116.
6. Stone E. An account of the success of the bark of the willow in the cure of agues. Philos Trans R Soc Lond [Biol]. 1763;53:195-200.
7. Bywaters EGL. The history of salicylates. In: Dixon ASJ, Smith MJH, Martin BK, Wood PNH, eds. Salicylates: An International Symposium. London, England: J & A Churchill Ltd; 1963:3-4.
8. Weissmann G. Aspirin. Sci Am. 1991;264:84-90.
9. Collier HOJ. Aspirin. Sci Am. 1963;209:96-108.
10. Maclagan T. The treatment of acute rheumatism by salicin. Lancet. 1876;1:342-343.
11. Tainter ML, Ferris AJ. Aspirin in Modern Therapy: A Review. New York, NY: Bayer Company; 1969:5-7.
12. Dreser H. Pharmakologisches uber aspirin (acetylsalicylsaure). Pflugers Arch. 1899;76:306-318.
13. Link KP, Overman RS, Sullivan WR, Nuebner CF, Scheel LD. Studies on hemorrhagic sweet clover disease. J Biol Chem. 1943; 147:463-473.
14. Goven CD. The effect of salicylate administration on the prothrombin time. J Pediatr. 1946;29:629-636.
15. Gibson PC. Salicylic acid for coronary thrombosis? Lancet. 1948; 1:965.
16. Gibson PC. Aspirin in the treatment of vascular diseases. Lancet. 1949;2:1172-1174.
17. Craven LL. Acetylsalicylic acid, possible preventive of coronary thrombosis. Ann West Med Surg. 1950;4:95.
18. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J. 1953;75:38-40.
19. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J. 1956;78:213-215.
20. Quick AJ. Bleeding time after aspirin ingestion. Lancet. 1968;1:50.
21. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968;47: 2169-2180.
22. O'Brien JR. Effects of salicylates on human platelets. Lancet. 1968;1:779-783.
23. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature. 1971;231:232-235.
24. Harrison MJG, Marshall J, Meadows JC, Russell RWR. Effect of aspirin in amaurosis fugax. Lancet. 1971;2:743-744.
25. Mundall J, Quintero P, von Kaulla KN, Harmon R, Austin J. Transient monocular blindness and increased platelet aggregability treated with aspirin. Neurology. 1972;22:280-285.
26. Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R. A randomized trial of acetyl-salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ. 1974;1:436-440.
27. The Coronary Drug Project Research Group. Aspirin in coronary heart disease. J Chronic Dis. 1976;29b:625-642.
28. Heikinheimo R, Jarvinen K. Acetylsalicylic acid and arterio-sclerotic-thromboembolic diseases in the aged. J Am Geriatr Soc. 1971;19:403-405.
29. Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. BMJ. 1974;1:440-443.
30. ISIS-2 Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988;2: 349-360.
31. Lewis HJ Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, Doherty J, Schnaper HW, LeWinter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: results of a Veterans Administration Cooperative Study. N Engl J Med. 1983;309:396-403.
32. Schmidt-Mulheim A. Beitrage zur kennt-niss des peptons und seiner physiologischen bedeutung. Du Bois-Reymond. Arch Physiol. 1880:33-35.
33. Wilander O. Studien uber heparin. Scand Arch Physiol. 1939;S15: 81:1-89.
34. Pavlov IP. Biokhimya Sventyvaniya Krovi. Kiev: YV Belik; 1957. Reprinted OTS Washington, February 1959. US Joint Publications Research Service.
35. Morawitz P. Die chemie der blutgerinnung. Ergeb Physiol. 1905; 4:307-423.
36. Biedl A, Kraus R. Experimentelle studien uber anaphylaxie. Wien Klin Wochenschr. 1909;22:363-374.
37. Doyon M, Morel A, Policard A. Estraition directe de l'antithrombine du foie: influence de la congelation. C R Soc Biol [Paris]. 1911;70:341-344.
38. McLean J. The discovery of heparin. Circulation. 1959;19:75-78.
39. Best CH. Preparation of heparin and its use in the first clinical cases. Circulation. 1959;19:79-86.
40. McLean J. The thromboplastic action of cephalin. Am J Physiol. 1916;41:250-257.
41. Howell WH, Holt E. Two new factors in blood coagulation-heparin and pro-antithrombin. Am J Physiol. 1918;47:328-341.
42. Howell WH. Heparin, an anticoagulant. Am J Physiol. 1922-3;63: 434-435.
43. Reinert M, Winterstein A. Contribution to the study of heparin. Arch Int Pharmacodyn Ther. 1939;62:447-468.
44. Silver JM, Turner DL, Tocantins LM. Lipid anticoagulants. Prog Hematol. 1959;2:264-281.
45. Howell WH, Holt E. The purification of heparin and its presence in the blood. Am J Physiol. 1925;71:553-562.
46. Howell WH, Holt E. The purification of heparin and its chemical and physiological reactions. Bull Johns Hopkins Hosp. 1928;42: 199-206.
47. Jaques LB. Addendum: the discovery of heparin. Semin Thromb Hemost. 1978;4;4:350-353.
48. Mason EC. A note on the use of heparin in blood transfusion. J Lab Clin Med. 1924;10:203-206.
49. Mason EC. Blood coagulation: the production and prevention of experimental thrombosis and pulmonary embolism. Surg Gynecol Obstet. 1924;39:421-428.
50. Reed CI. The intravascular use of heparin. Am J Physiol. 1925; 74:79-81.
51. Shionoya T. Studies in experimental extra-corporeal thrombosis. III. Effects of certain anticoagulants (heparin and hirudin) on extracorporeal thrombosis and on the mechanism of thrombus formation. J Exp Med. 1927;46:19-26.
52. Godlowski Z. Die heparin (antiprothrombin) Verwendung zwecks funktionsprufung des menschlichen retikulo-endothelialen systems. Wein Med Wochenschr. 1933;83:1034-1037.
53. Best CH. Heparin and thrombosis. Harvey Lectures. 1940;Nov: 66-90.
54. Charles AF, Scott DA. Studies on heparin: I. The preparation of heparin. J Biol Chem. 1933;102:425-429.
55. Charles AF, Scott DA. Studies on heparin: IV. Observations on the chemistry of heparin. Biochem J. 1936;30:1927-1933.
56. Schmitz A, Fischer A. Uber die chemisches natur des heparins. II. Die reindarstellung des heparins. Zeit Physiol Chem. 1933;216: 264-269.
57. Jorpes E. On heparin, its chemical nature and properties. Acta Med Scand. 1936;88:427-433.
58. Hedenius P, Wilander O. The influence of intravenous injections of heparin in man on the time of coagulation. Acta Med Scand. 1936;88:443-449.
59. Crafoord C. Preliminary report on post-operative treatment with heparin as a preventive of thrombosis. Acta Chir Scand. 1937;79: 407-426.
60. Murray DWG, Jaques LB, Perrett TS, Best CH. Heparin and the thrombosis of veins following injury. Surgery. 1937;2:163-187.
61. Wetterdal P. The use of heparin as a prophylactic against thrombosis following gynecologic operations. Acta Med Scand. 1941;107:123-126.
62. Leissner H. The use of heparin in obstetric practice as a means of preventing thrombosis. Acta Med Scand. 1941;107:127-130.
63. Holmin N, Ploman KG. Thrombosis of central vein of retina treated with heparin. Lancet. 1938;1:664-665.
64. Jorpes JE. Heparin: a mucopolysaccharide and an active antithrombotic drug. Circulation. 1959;19:87-91.
65. Magnusson JH. Thrombosis of the posterior inferior cerebellar artery (Wallenberg syndrome) treated with heparin. Lancet. 1938; 1:666-667.
66. Bauer G. The introduction of heparin therapy in cases of early thrombosis. Circulation. 1959;19:108-109.
67. Wright IS. Experience with anticoagulants. Circulation. 1959;19: 110-113.
68. Waters ET, Markowitz J, Jaques LB. Anaphylaxis in the liverless dog, and observations on the anticoagulant of anaphylactic shock. Science. 1938;87:582-583.
69. Chargaff E, Olson KB. Studies on the chemistry of blood coagulation. VI. Studies on the action of heparin and other anticoagulants: the influence of protamine on the anticoagulant effect in vivo. J Biol Chem. 1937;122:153-167.
70. Brinkhous KM, Smith HP, Warner ED, Seegers WH. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am J Physiol. 1939;125:683-687.
71. Hirsh J. Heparin. N Engl J Med. 1991;324:1565-1574.
72. Abildgaard U. Highly purified antithrombin III with heparin cofactor activity prepared by disc electrophoresis. Scand J Clin Lab Invest. 1968;21:89-91.
73. Schofield FW. Hemorrhagic sweet clover disease in cattle. Can Vet Rec. 1922;3:74-75.
74. Schofield FW. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. J Am Vet Med Assoc. 1924;64:553-572.
75. Roderick LM. The pathology of sweet clover disease in cattle. J Am Vet Med Assoc. 1929;74:314-325.
76. Roderick LM. Problems in the coagulation of the blood: "sweet clover disease of cattle." Am J Physiol. 1931;96:413-425.
77. Dam H. Cholesterinstoffwechsel in huhnereiern und huhnchen. Biochem Z. 1929;215:475-492.
78. Dam H. Antihemorrhagic vitamin of the chick: occurrence and chemical nature. Nature. 1935;135:652-653.
79. Almquist JH, Stohstad ELR. Dietary hemorrhagic disease in chicks. Nature. 1935;136:31.
80. Thayer SA, MacCorquadale DW, Brinkley SB, Doisy EA. Isolation of crystalline compound with vitamin K activity. Science. 1938;88:243.
81. Link KP. The discovery of dicumarol and its sequels. Circulation. 1959;19:97-107.
82. Link KP. The anticoagulant from spoiled sweet clover hay. Harvey Lectures. 1943-44;34:162-207.
83. Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci. 1935;190:501-511.
84. Quick AJ. The coagulation defect in sweet clover disease and in the hemorrhagic chick disease of dietary origin. Am J Physiol. 1937;118:260-271.
85. Campbell HA, Roberts WL, Smith WK, Link KP. Studies of the hemorrhagic sweet clover disease: I. The preparation of hemorrhagic concentrates. J Biol Chem. 1940;136:47-55.
86. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease: V. Identification and synthesis of the hemorrhagic agent. J Biol Chem. 1941;138:513-527.
87. Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease: VI. The synthesis of the delta-diketone derived from the hemorrhagic agent through alkaline degradation. J Biol Chem. 1941;138:529-534.
88. Meyer O, Bingham JB, Pohle FJ. Read before the University of Wisconsin Medical Society, February 27, 1941.
89. Butt HR, Allen EV, Bollman JL. A preparation from spoiled sweet clover [3,3′-methylene-bis-(4-hydroxycoumarin)] which prolongs coagulation and prothrombin time of the blood: preliminary report of experimental and clinical studies. Proc Staff Meet, Mayo Clin. 1941;16:388-395.
90. Bingham JB, Meyer OO, Pohle FJ. Studies on the hemorrhagic agent 3,3′-methylene-bis-(4-hydroxycoumarin): I. Its effect on the prothrombin and coagulation time of the blood of dogs and humans. Am J Med Sci. 1941;202:563-578.
91. Prandoni A, Wright I. The anticoagulants heparin and the dicoumarin 3,3′-methylene-bis-(4-hydroxycoumarin). Read before the Graduate Fortnight of the New York Academy of Medicine, October 1941.
92. Prandoni A, Wright I. The anticoagulants heparin and the dicoumarin 3,3′-methylene-bis-(4-hydroxycoumarin). Bull NY Acad Med. 1942;18:433-458.
93. Allen EV, Barker NW, Waugh JM. A preparation from spoiled sweet clover. JAMA. 1942:1009-1015.
94. Nichol ES, Page SW. Dicumarol therapy in acute coronary thrombosis: results in fifty attacks. J Fla Med Assoc. 1946;32:365-370.
95. Wright IS. Experience with dicumarol (3,3′-methylene-bis-[4-hydroxycoumarin]) in the treatment of coronary thrombosis with myocardial infarction. Am Heart J. 1946;32:20-31.
96. Wright IS, Marple CD, Beck DF. Report of the committee for the evaluation of anticoagulants in the treatment of coronary thrombosis with myocardial infarction. Am Heart J. 1948;36: 801-815.
97. Ikawa M, Stahmann MA, Link KP. Studies on 4-hydroxycoumarins. V. The condensation of alpha, beta-unsaturated ketones with 4-hydroxycoumarin. J Am Chem Soc. 1944;66: 902-906.
98. Shapiro S. Warfarin sodium derivative (coumadin sodium): intravenous hypoprothrombinemia-inducing agent. Angiology. 1953;4: 380-390.
99. Clatanoff DV, Triggs PO, Meyer OO. Clinical experience with coumarin anticoagulants warfarin and warfarin sodium. Arch Int Med. 1954;94:213-220.
100. Pollock BE. Clinical experience with warfarin (coumadin) sodium, a new anticoagulant. JAMA. 1955;159:1094-1097.
101. Stenflo J, Fernlund P, Egan W, Roepstorft P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A. 1974;71:2730-2733.
102. Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry. 1978;17:1371-1377.
103. Bell RG. Metabolism of vitamin K and prothrombin synthesis: anticoagulants and the vitamin K-epoxide cycle. Fed Proc. 1978; 37:2599-2604.
104. Fink E. Comparison of hirudins. Semin Thromb Hemost. 1989;15; 3:283-287.
105. von Brucke E. Die verdauende substanz im urin. SB Akad Wiss (Vienna). 1861;43:601-615.
106. Sahli W. Uber das vorkommen non pepsin und trypsin in mornaled menschlichen harn. Pflugers Arch Physiol. 1886;38: 35-93.
107. MacFarlane RG, Pilling J. Fibrinolytic activity in normal urine. Nature. 1947;159:779.
108. Williams JRB. The fibrinolytic activity of the urine. Br J Exp Pathol. 1951;32:530-537.
109. Sobel GW, Mohler SR, Jones NW, Dowdy ABC, Guest MM. Urokinase: an activator of plasma profibrinolysin extracted from urine. Am J Physiol. 1952;171:768-769.
110. Sherry S. Personal reflections on the development of thrombolytic therapy and its application to acute coronary thrombosis. Am Heart J. 1981;102:1134-1139.
111. Tillett WS, Garner RL. The fibrinolytic activity of streptococci. J Exp Med. 1933;58:485-502.
112. Dastre A. Fibrinolyse dans le sang. Arch Norm Pathol. 1893;5: 661-663.
113. Yudin SS. Transfusion of cadaver blood. JAMA. 1936;106: 997-999.
114. Milstone H. A factor in normal human blood which participates in streptococcal fibrinolysis. J Immunol. 1941;42:109-116.
115. Christensen LR, MacLeod M. A proteolytic enzyme of serum: characterization, activation, and reaction with inhibitors. J Gen Physiol. 1945;28:363-383.
116. Kaplan MH. Nature and role of the lytic factor in hemolytic streptococcal fibrinolysis. Proc Soc Exp Biol Med. 1944;57:40-43.
117. Sherry S. The origin of thrombolytic therapy. J Am Coll Cardiol. 1989;14:1085-1092.
118. Tillett WS, Sherry S. The effect in patients of streptococcal fibrinolysin (streptokinase) and streptococcal desoxyribonuclease on fibrinous, purulent, and sanguinous pleural exudations. J Clin Invest. 1949;28:173-190.
119. Johnson AJ, Tillett WS. Lysis in rabbits of intravascular blood clots by the streptococcal fibrinolytic system (streptokinase). J Exp Med. 1952;95:449-464.
120. Sherry S, Fletcher AP, Alkjaersig N, Smyrniotis FE. An approach to intravascular fibrinolysis in man. Trans Assoc Am Physicians. 1957;70:288-296.
121. Fletcher AP, Alkjaersig N, Smyrniotis FE, Sherry S. Treatment of patients suffering from early, myocardial infarction with massive and prolonged streptokinase therapy. Trans Assoc Am Physicians. 1958;71:287-296.
122. Fletcher AP, Alkjaersig N, Sherry S. The maintenance of a sustained thrombolytic state in man. I. Induction and effects. J Clin Invest. 1959;38:1096-1100.
123. Fletcher AP, Sherry S, Alkjaersig N, Smyrniotis FE, Jack S. The maintenance of a sustained thrombolytic state in man. II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest. 1959;38:1111-1119.
124. Johnson AJ, McCarty WR. The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. J Clin Invest. 1959;38:1627-1643.
125. Fletcher AP, Alkjaersig N, Sherry S, Genton E, Hirsh J, Bachmann F. Development of urokinase as a thrombolytic state in man by its intravenous infusion. J Lab Clin Med. 1965;656: 713-731.
126. Urokinase Pulmonary Embolism Trial. A National Cooperative Study. Circulation. 1973;47(suppl II):II-1-II-108.
127. Stampfer MJ, Goldhaber SZ, Yusuf S, Peto R, Hennekens CH. Effects of intravenous streptokinase on acute myocardial infarction: results pooled from randomized trials. N Engl J Med. 1982;307:1180-1182.
128. Yusuf S, Collins R, Peto R, Furberg C, Stampfer MJ, Goldhaber SZ, Hennekens CH. Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction, and side effects from 33 randomized controlled trials. Eur Heart J. 1985;6:556-585.
129. Ruegsegger P, Nydick I, Abarquez R, Reichel F, Cliffton E, LaDue JS. Effect of fibrinolytic (plasmin) therapy on the physiopathology of myocardial infarction. Am J Cardiol. 1960;6:519-524.
130. Boucek RJ, Murphy WP, Sommer LS, Voudoukis IJ. Segmental perfusion of the coronary arteries with fibrinolysin in man following a myocardial infarction. Am J Cardiol. 1960;6:525-533.
131. Richter IH, Musacchio F, Cliffton EE, Nassar A, Kaplan L, Favazza AG, Akbari A. Experiences with clot-lysing agents in coronary thrombosis. Am J Cardiol. 1960;6:534-537.
132. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS, Lang HT. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med. 1980;303:897-902.
133. Chazov EL, Mateeva LS, Mazaev AV, Sargin KE, Sadovshaya M, Ruda Y. Intracoronary administration of fibrinolysin in acute myocardial infarction. Ter Arkh. 1976;48:8-19.
134. Rentrop KP, Blanke H, Kostering K, Karsch KR. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase in combination with transluminal recanalization. Clin Cardiol. 1979;2:354-363.
135. Smith RAG, Dupe RJ, English PD, Green J. Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy. Nature. 1981;290:505-508.
136. Been M, de Bono DB, Muir AL, Boulton FE, Hillis WS, Hornung R. Coronary thrombolysis with intravenous APSAC. Br Heart J. 1985;53:253-259.
137. Astrup T, Permin PM. Fibrinolysis in animal organism. Nature. 1947;159:681-682.
138. Bachmann F, Alkjaersig N, Fletcher AP, Sherry S. Partial purification and properties of plasminogen activator from pig heart. Biochemistry. 1964;3:1578-1585.
139. Rijken DC, Wijngaards G, Zaal-De Jong M, Welbergen J. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta. 1979;580: 140-153.
140. Rijken DC, Collen D. Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. J Biol Chem. 1981;256:7035-7041.
141. Binder BR, Spragg J, Austen KF. Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates. J Biol Chem. 1979;254:1998-2003.
142. Pennica D, Holmes WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelveston E, Seeburg PH, Heyneker HL, Goeddel DV, Collen D. Cloning and expression of human tissue-type plasminogen activator cDNA in E coli. Nature. 1983; 301:214-221.
143. Van de Werf F, Ludbrook PA, Bergmann SR, Tiefenbrunn AJ, Fox KAA, de Geest H, Verstraete M, Collen D, Sobel BE. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med. 1984; 310:609-613.
144. Van de Werf F, Bergmann SR, Fox KAA, de Geest H, Hoyng CF, Sobel BE, Collen D. Coronary thrombolysis in dogs with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1984;69: 605-610.
145. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robison AK, Hutter AM, Bell WR, Spadaro JJ, An Khaw B, Brossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984;69:1012-1017.